BRIEF-Cytokinetics And Bayer Announce Exclusive Licensing Collaboration For Aficamten In Japan

Reuters
2024-11-19
BRIEF-<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> And Bayer Announce Exclusive Licensing Collaboration For Aficamten In Japan

Nov 19 (Reuters) - Cytokinetics Inc CYTK.O:

  • CYTOKINETICS AND BAYER ANNOUNCE EXCLUSIVE LICENSING COLLABORATION FOR AFICAMTEN IN JAPAN

  • CYTOKINETICS INC - TO RECEIVE €50 MILLION UPFRONT, UP TO €90 MILLION IN MILESTONES

  • CYTOKINETICS INC - ELIGIBLE FOR UP TO €490 MILLION IN COMMERCIAL MILESTONES

  • CYTOKINETICS INC - BAYER TO CONDUCT PHASE 3 TRIAL IN JAPANESE PATIENTS WITH OBSTRUCTIVE HCM

Source text: ID:nGNXsZdWX

Further company coverage: CYTK.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10